
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is expected to continue its strong performance in the healthcare industry, driven by its diverse portfolio and strategic investments in new products and markets. The company's decision to separate its Orthopaedics business and focus on M&A in the MedTech sector shows its commitment to long-term growth and innovation. With a strong financial position and a positive outlook, Johnson & Johnson is well-positioned for continued success in the healthcare market.
Bears say
Johnson & Johnson is a diversified healthcare company, with a focus on innovative medicine and medtech. Despite solid sales growth in 2025 from its MedTech division, there are concerns about market expansion and competitive headwinds in this segment. Additionally, JNJ faces the risk of loss of exclusivity for key drugs and pricing pressures in the pharmaceutical industry. The company's focus on M&A and ongoing litigations add further uncertainty to its outlook. While the company has shown promising potential with new product launches, it may face challenges in maintaining its growth in the highly regulated healthcare industry.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares